5.0 Patient Selection 
5.1 A diagnosis of epithelial ovarian carcinoma must be established 
histologically. 
5.2 Patients may initially have been Stage I, II, or III. Stage IV patients 
initially or at present are not eligible. 
5.3 Patients must have completed the initial surgery and/or chemotherapy 
and have been off treatment for at least 6 weeks. Previous 
chemotherapy must have included cisplatin or carboplatin containing 
regimens. 
5.4 Patients must have clinical evidence of recurrent, progressive or 
residual disease by imaging, physical examination, surgery, or 
successive elevation of the CA 125 marker. If possible, persistence or 
progression should be documented by histology/cytology. If CA 125 is 
used as evidence of residual disease, then the level must be greater than 
35 lU/ml and increasing on two successive determinations, greater than 
1 month apart, and the patient must not have had a laporotomy within the 
preceding 3 months. 
5.5 The patients performance status must be 0 or 1 by ECOG standards. 
5.6 Any tumor masses found by imaging must be 2.0 cm or less to be eligible 
for this study. 
5.7 Adequate bone marrow, kidney and liver function must be shown by: 
Hct > 30, WBC > 4,000, platelets > 100,000, creatinine <1.5 mg%, 
Creat. Cl > 50, normal bilirubin, SGOT and alkaline phosphatase 
< 1 .5 x normal. 
5.8 Patients must not have a significant history of heart disease (frequent 
angina, Ml within the past 6 mos., congestive heart failure requiring 
daily treatment). 
5.9 A patient is not eligible if there : s a history of a previous malignancy, 
other than squamous or basal cell carcinoma of the skin. Patients with 
childbearing potential are not eligible. 
6.0 Study Design 
This is a phase I study to determine the toxicity and safety of administering HSV- 
TK modified ovarian tumor cells I.P with subsequent ganciclovir therapy. The 
[ 594 ] 
Recombinant DNA Research, Volume 15 
